



(11) **EP 1 312 259 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
23.12.2009 Bulletin 2009/52

(21) Application number: **01958410.1**

(22) Date of filing: **23.08.2001**

(51) Int Cl.:
A01K 67/027 (2006.01) **A61K 45/00** (2006.01)
A61P 37/08 (2006.01) **G01N 33/15** (2006.01)
G01N 33/50 (2006.01) **G01N 33/53** (2006.01)

(86) International application number:
PCT/JP2001/007196

(87) International publication number:
WO 2002/015680 (28.02.2002 Gazette 2002/09)

(54) **TYPE III ALLERGIC INFLAMMATION MODEL ANIMAL**

TIERMODELL FÜR TYP III ALLERGISCHE ENTZÜNDUNGEN

MODELE ANIMAL PERMETTANT D'ÉVALUER L'INFLAMMATION ALLERGIQUE DE TYPE III

(84) Designated Contracting States:
CH DE FR GB LI

(30) Priority: **24.08.2000 JP 2000253984**

(43) Date of publication of application:
21.05.2003 Bulletin 2003/21

(73) Proprietor: **Japan Science and Technology Agency**
Kawaguchi-shi,
Saitama 332-0012 (JP)

(72) Inventors:
• **TAKAI, Toshiyuki**
Sendai-shi, Miyagi 981-0952 (JP)
• **ONO, Masao**
Sendai-shi, Miyagi 981-0935 (JP)
• **YUASA, Takae**
Osakasayama-shi,
Osaka 589-0022 (JP)
• **WATANABE, Takeshi**
Saga-shi, Saga 849-0934 (JP)

(74) Representative: **Harding, Charles Thomas et al**
D Young & Co
Briton House
Briton Street
Southampton
SO14 3EB (GB)

(56) References cited:
WO-A1-97/14791 US-A- 5 859 314

- **YUASA T ET AL: "Lyn is essential for Fc[gamma] receptor III-mediated systemic anaphylaxis but not for the arthus reaction" JOURNAL OF EXPERIMENTAL MEDICINE 05 MAR 2001 UNITED STATES, vol. 193, no. 5, 5 March 2001 (2001-03-05), pages 563-571, XP002426009 ISSN: 0022-1007**
- **DE ANDRES BELEN ET AL: "A regulatory role for Fcgamma receptors (CD16 and CD32) in hematopoiesis" IMMUNOLOGY LETTERS, vol. 68, no. 1, 3 May 1999 (1999-05-03), pages 109-113, XP002426010 ISSN: 0165-2478**
- **DE ANDRES BELEN ET AL: "A regulatory role for Fcgamma receptors CD16 and CD32 in the development of murine B cells" BLOOD, vol. 92, no. 8, 15 October 1998 (1998-10-15), pages 2823-2829, XP002426011 ISSN: 0006-4971**
- **WANG JIYANG ET AL: "Altered antigen receptor signaling and impaired fas-mediated apoptosis of B cells in Lyn-deficient mice" JOURNAL OF EXPERIMENTAL MEDICINE, vol. 184, no. 3, 1996, pages 831-838, XP002426012 ISSN: 0022-1007**
- **NISHIZUMI H ET AL: "A double-edged kinase lyn: A positive and negative regulator for antigen receptor-mediated signals" JOURNAL OF EXPERIMENTAL MEDICINE 20 APR 1998 UNITED STATES, vol. 187, no. 8, 20 April 1998 (1998-04-20), pages 1343-1348, XP002426013 ISSN: 0022-1007**
- **HIBBS M.L. ET AL.: 'Multiple defects in the immune system of lyn-deficient mice, culminating in autoimmune disease' CELL vol. 83, 1995, pages 301 - 311, XP002947286**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 312 259 B1

- OLIVER J.M. ET AL.: 'Immunologically mediated signaling in basophils and mast cells: finding therapeutic targets for allergic diseases in the human FcepsilonR1 signaling pathway' IMMUNOPHARMACOLOGY vol. 48, 25 July 2000, pages 269 - 281, XP002947287
- TAKAI T. ET AL.: 'Regulation of murine hypersensitive responses by Fc receptors' ALLERGOLOGY INTERNATIONAL vol. 47, no. 2, 1998, pages 75 - 83, XP002947288
- TOSHIYUKI TAKAI: 'Fc receptor bunshi-gun ni yoru men-eki seigyō' KAREIIGAKU KENKYUSHO ZASSHI vol. 49, no. 3,4, 1998, pages 107 - 118, XP002947289

Description

Technical Field

[0001] The present invention relates to an experimental model animal for type III allergy inflammation that does not develop anaphylaxis, a type I allergy, and can specifically induce Arthus reaction, a type III allergy, and to a method of screening a reaction accelerating or inhibitory substance in a type III allergy reaction through Fc γ RIII by using said experimental model animal.

Background Art

[0002] It is known that immunoglobulin (Ig) is found in the body fluids of all vertebrate animals from fish to mammals, and is produced by lymphoid cells. It is classified into five classes, namely, IgG, IgM, IgA, IgD and IgE, according to the physicochemical and immunological properties, wherein the fundamental structure of molecules are common to each class, and is composed from H chain having fifty to seventy thousand molecular weight and L chain having twenty-three thousand molecular weight, and the H chain is structured with γ , μ , α , δ , and ϵ chain corresponding to IgG, IgM, IgA, IgD and IgE. The two H chains from the hinge region to the C terminal obtained by decomposing this Ig molecule with papain, which are bound by S-S binding is called a Fc fragment, and the receptor on the cell surface which this Fc fragment binds to is called a Fc receptor (hereinafter "FcR"). It is known that these FcRs derive signaling in the cells and crosslink by antigen-antibody complex which is a ligand, thereby constructing a hematopoietic cell surface molecule family that induces the response of many effectors. Further, it is known that FcR, which shows affinity to the Fc region of Ig and exists on the cell surface, is involved in immunoresponses such as antibody-dependent cytotoxic reaction and hypersensitive reaction.

[0003] The types of FcRs known are Fc γ receptor that binds specifically to the γ chain of IgG in the body fluid, Fc ϵ receptor that binds specifically to the E chain of IgE, Fc α R that binds specifically to the α chain of IgA, and the like. It is known that the Fc receptors of these immunocompetent cells have a significant relationship with cell function, and that many of them exist in the large portion of lymphocyte, a part of the T cell lymphocyte, mononuclear cell, neutrophil, basophil, macrophage, mastocyte (mast cell), platelet or the like. Further, these receptors play a role in the function of lymphocyte that is antibody-dependent, however, its inherent function is poorly understood. Fc γ receptor (hereinafter "Fc γ R") is classified mainly into three types, type I (CD64 antigen), type II (CD32 antigen) and type III (CD16 antigen), based on the similarity of gene structure. It is known that Fc γ RI is a glycoprotein with a molecular weight of 72 kDa, which binds to the IgG monomer with high affinity, and expresses on the monocyte and macrophage. Fc γ RII differs from the other FcRs in that it has low affinity to the IgG mon-

omer, binds to the polyvalent IgG that has become an immunocomplex, and is widely expressed in the hematopoietic stem cells including monocyte, macrophage, polymorphonuclear (PMN) leukocyte, mast cell, platelet, some of the T cell lymphocytes and B cell lymphocytes. Further, it is known that Fc γ RIII is a low-affinity Fc γ R, which expresses in natural killer cell, macrophage, PMN and mast cell. It is also known that three types of receptors having different gene arrangements, Fc γ RIIA, Fc γ RIIB and Fc γ RIIC, exist in Fc γ RII, and that each of its chromosome is positioned in 1q23.

[0004] Recently, knockout mice for these FcR molecular groups have been generated continuously (Cell 75, 969-976, 1993; Cell 76, 519-529, 1994; Nature 379, 346-349, 1996; Immunity 5, 181-188, 1996; Nature 369, 753-756, 1994; J. Immunol. 152, 3378-3390, 1994; Proc. Natl. Acad. Sci. USA 91, 6835-6839, 1994), and the understanding of the physiological function of some of the FcRs have progressed. Moreover, the present inventors have generated a knockout mouse of For γ chain isolated and identified as a homodimeric molecule that is associated with Fc ϵ RI, which is a high-affinity receptor of IgE (Cell, 76, 519-529, 1994). It is also known that this Fc γ chain knockout mouse is deficient in the expression and function of FcR, at least in the three types of Fc γ RI, Fc γ RIII and Fc ϵ RI.

[0005] The FcR that expresses in the immunocytic group mentioned above is a molecule that begins various immunoreaction and inflammatory response to antibody dependency. Since FcR expresses by duplicating in multiple cell species, the role of individual FcRs became clear only after several mice whose FcR expression is genetically deficient was generated. Presently, it has been revealed that the role of FcR is involved in the onset of diseases such as allergy (Cell 75, 969-976, 1993; Cell 76, 519-529, 1994), Arthus reaction (Science 265, 1095-1098, 1994; Immunity 5, 387-390), rheumatoid arthritis (J. Exp. Med. 189, 187-194, 1999; J. Exp. Med. 191, 1611-1616, 2000), immunologic glomerulonephritis (Kidney Int. 54, 1166-1174, 1998; Eur. J. Immunol. 30, 1182-1190, 2000), autoimmune vasculitis (Blood 94, 3855-3863, 1999), systemic lupus erythematosus (Science 279, 1052-1054, 1998) and Goodpasture's syndrome (Goodpasture's; J. Exp. Med. 191, 899-906, 2000), as well as biophylaxis. Moreover, the essential role of FcR in the various immune processes is progressively elucidated by the finding of the mutate mouse mentioned above (Annu. Rev. Immunol. 16, 421-432, 1998; Annu. Rev. Immunol. 15, 203-234, 1997; Takai, T., and J. V. Ravetch. 1998. Fc receptor genetics and the manipulation of genes in the study of FcR biology. In Immunoglobulin Receptors and their Physiological and Pathological Roles in Immunity. J. G. J. van de Winkel and P. Mark Hogarth, editors. Kluwer Academic Publishers, Netherland, 37-48).

[0006] It has also been reported that the Fc γ RIII on the mast cell plays a primary role at the start of the two types of distinct immunoresponses, that is, IgG-depend-

ent anaphylaxis (J. Clin. Invest. 99, 915-925, 1997; J. Clin. Invest. 99, 901-914, 1997; J. Exp. Med. 189, 1573-1579, 1999) and passive Arthus reaction (Science 265, 1095-1098, 1994; Immunity 5, 387-390, J. Exp. Med. 184, 2385-2392, 1996; Immunity 5, 181-188, 1996; Eur. J. Immunol. 30, 481-490, 2000). These immunore-sponsive models are distinguished from one another by the difference of the period of development of the disease and histology. In anaphylaxis, skin edema and systemic blood supply failure (shock) are developed immediately after antigen exposure. In contrast, Arthus reaction is found a few hours after antigen exposure, as a tissue damage accompanied by hemorrhage. Presently, the formation of pathology of models that indicate these char-acteristics, are explained as a result of time-limited dis-charge of inflammatory mediator, for example, the pre-existing substances such as histamine and serotonin, and substances that are newly synthesized such as ara-chidonic acid metabolite and cytokine. However, the in-tracellular mechanism involved in the development of pa-thology of these models remains unclear.

[0007] Meanwhile, it is known that Lyn belongs to the Src family kinase, associates with a variety of immunore-ceptors that have ITAM motif (an amino acid sequence that is recognized and bound by the SH2 region of the intracellular tyrosine kinase), and has a function to begin intracellular signaling (Int. J. Biochem. Cell. Biol. 29, 397-400, 1997; Annu. Rev. Immunol. 17, 555-592, 1999). In a recent research using a Lyn deficient mouse, it was revealed that Lyn plays an essential role in the individual body, for B cells and mast cells to function normally (Cell 83, 301-311, 1995; Immunity 3, 549-560, 1995; Immunity 7, 69-81, 1997). In fact, in a Lyn deficient mouse, marked damage is shown in the cutaneous anaphylaxis reaction which is induced by IgE and antigen, and Lyn plays an important role in the signaling through Fc ϵ RI (J. Immunol. 158, 2350-2355, 1997).

[0008] As mentioned above, Lyn tyrosine kinase, which belongs to the Src family, associates functionally with a variety of receptors such as FcR and the like, and plays a significant role in intracellular signaling. In con-trast, in an inflammatory response such as autoimmune disease, allergy reaction or the like, wherein the immu-nocomplex is involved, the role of the Fc γ R of IgG ex-pressed in mast cells and the like are drawing attention. For example, it was revealed by research using knockout mice that Fc γ R1III activates mast cells through the immu-nocomplex, and on the contrary, Fc γ R1IB inhibits mast cells. However, it was not possible to make an evaluation of type III allergy inflammation independently, since nor-mally, the Fc γ R1IB shows inhibitory action. An object of the present invention is to provide an experimental model animal that does not develop anaphylaxis, a type I allergy, can specifically induce Arthus reaction, a type III allergy, and can independently evaluate the type III allergy in-flammation without being affected by type I allergy, and a method of screening a reaction accelerating or inhibi-tory substance in a type III allergy reaction through Fc-

γ R1III using said experimental model animal.

[0009] The inventors of the present invention have conducted intensive study to attain the object mentioned above, and generated a double deficient mouse of Lyn and Fc γ R1IB in order to eliminate Fc γ R1IB which inhibits the response through Fc γ R1III. The significance of the role of Lyn in the downstream of Fc γ R1III signaling was studied by inducing systemic passive anaphylaxis with IgG-immunocomplex. From the fact that systemic pas-sive anaphylaxis is Lyn-requisite and reverse passive Arthus reaction is not Lyn-requisite, the pathway con-nected to the allergy response through Fc γ R1III has two pathways, Lyn-dependent and Lyn-independent, and the inventors focused attention on the function of Lyn-inde-pendent pathway in type III allergy reaction. Thus, the present invention had been completed.

Disclosure of the Invention

[0010] The present invention relates to a non-human model animal for type III allergy inflammation wherein the genetic function of Lyn and Fc γ R1IB are deficient on its chromosome wherein the animal does not develop ana-phyllaxis, a type I allergy, and specifically induces Arthus reaction, a type III allergy (claim 1); the non-human model animal for type III allergy inflammation according to claim 1, wherein the non-human animal is a rodent (claim 2); and the non-human model animal for type III allergy inflam-mation according to any of claims 1 or 2, wherein the rodent is a mouse (claim 3).

[0011] Further, the present invention relates to a meth-od of screening a reaction accelerating or inhibitory sub-stance in a type III allergy reaction through Fc γ R1III, wherein a subject material is administered to the non-human model animal for type III allergy inflammation ac-cording to any of claims 1 to 3, followed by determination and evaluation of Fc γ R1III function of the non-human animal (claim 4); the method of screening a reaction accel-erating or inhibitory substance in a type III allergy reaction through Fc γ R1III according to claim 4, wherein the deter-mination and evaluation of Fc γ R1III function of the non-human animal is a determination and evaluation of en-dorectal temperature after administration of antigen, with a systemic passive anaphylaxis response intensity as an index (claim 5); the method of screening a reaction ac-celerating or inhibitory substance in a type III allergy re-action through Fc γ R1III, wherein a bone marrow-derived mast cell induced from a bone marrow cell derived from the non-human model animal for type III allergy inflam-mation according to any of claims 1 to 3, is contacted with a subject material in vitro, followed by determination and evaluation of Fc γ R1III function of the bone marrow-derived mast cell (claims 6); the method of screening a reaction accelerating or inhibitory substance in a type III allergy reaction through Fc γ R1III according to claim 6, wherein the determination and evaluation of Fc γ R1III func-tion of the bone marrow-derived mast cell is a determi-

nation and evaluation of degranulation ability of mast cell, cytoplasmic calcium dynamics of mast cell, or tyrosine phosphorylation of total protein of mast cell (claim 7) ; the method of screening a reaction accelerating or inhibitory substance in a type III allergy reaction through the Fc γ R111 according to any of claims 4 to 7 wherein the method uses the non-human model animal for type III allergy inflammation according to any of claims 1 to 3 and a non-human animal wherein the genetic function of Fc γ I1B is deficient on its chromosome(claim 8). Also described is a remedy for diseases caused by type III allergy reaction, wherein an inhibitory substance obtained from the method of screening a reaction accelerating or inhibitory substance in a type III allergy reaction through the Fc γ R111 according to any of claims 5 to 9 is used as an active ingredient

Brief Description of Drawings

[0012]

Figure 1 is a view showing the results from monitoring the systemic passive anaphylaxis in the double deficient mice (Lyn I1B $^{-}$) of the present invention and control mice (I1B $^{-}$), by endorectal temperature determination

Figure 2 is a view showing the results from monitoring the degranulation ability of bone marrow-derived mast cell of the double deficient mice (Lyn I1B $^{-}$) of the present invention and control mice (I1B $^{-}$), by serotonin quantitative determination.

Figure 3 is a view showing the results from determination of intracellular Ca $^{2+}$ dynamics of bone marrow-derived mast cell (A) and tyrosine phosphorylation of cell total proteins (B) of the double deficient mice (Lyn I1B $^{-}$) of the present invention and control mice (I1B $^{-}$) which are induced by cross linkage of FcR.

Figure 4 is a view showing the results from determination of cytokine discharge from bone marrow-derived mast cell of the double deficient mice (Lyn I1B $^{-}$) of the present invention and control mice (I1B $^{-}$) which is induced by cross linkage of Fc γ R111.

Figure 5 is a view showing the MPO activity of the inflammation site (A) and histological change (B) of the reverse cutaneous passive Arthus reaction of the double deficient mice (Lyn I1B $^{-}$) of the present invention and control mice (I1B $^{-}$) induced by IgG-immunocomplex.

Best Mode of Carrying Out the Invention

[0013] As the non-human model animal for type III allergy inflammation of the present invention, there is no particular limitation as long as it is a non-human animal which does not develop anaphylaxis, a type I allergy, and specifically induces Arthus reaction, a type III allergy and wherein the genetic function of Lyn and Fc γ I1B are both

deficient on its chromosome can be specifically exemplified. The non-human animal wherein the genetic function of Lyn and Fc γ I1B are both deficient on its chromosome refers to, for example, a non-human animal wherein a part or the whole of the endogenous gene of non-human animal that encodes Lyn and Fc γ I1B are inactivated by gene mutation such as disruption, deficiency, substitution and the like, and the function to express Lyn and Fc γ I1B in a wild-type is lost, or the like. Further, as the non-human animal in the present invention, rodents such as mice, rats, guinea pigs and the like can be specifically exemplified, but are not limited to these examples. The method of generating the non-human animal wherein the genetic function of Lyn and Fc γ I1B are both deficient on its chromosome will now be explained, by giving mice wherein the genetic function of Lyn and Fc γ I1B are both deficient on its chromosome as an example.

[0014] First, mice wherein the genetic function of Lyn is deficient on its chromosome, that is, Lyn knockout mice (Lyn $^{-/-}$), are generated. Lyn knockout mice can be generated by the method as previously described (Immunity 3, 549-560, 1995), or the like. Specifically, a gene fragment obtained from a mouse gene library by methods such as PCR or the like is used to screen a Lyn gene. With the recombinant DNA technique, a part or the whole of the Lyn gene that was screened is substituted with a marker gene such as neomycin-resistant gene or the like. A targeting vector is constructed by introducing genes such as diphtheria toxin A fragment (DT-A) gene, herpes simplex virus thymidine kinase (HSV-tk) gene or the like into the 5' end side. This targeting vector that was constructed is linearized, and introduced into ES cells by methods such as electroporation or the like. Homologous recombination is conducted, and among its homologous recombinants, ES cells that indicate resistance to antibiotics such as G418, ganciclovir (GANC) and the like are selected. It is preferable to confirm whether the selected ES cells are the aimed recombinants, by methods such as Southern blot or the like.

[0015] The recombinant ES cells mentioned above are microinjected into the blastocysts of mice, said blastocysts are returned to the tentative parent mice, and chimeric mice are generated. These chimeric mice are mated with wild-type mice to obtain heterozygous mice, and these heterozygous mice are mated to obtain Lyn knockout mice. As a method to confirm whether the genetic function of Lyn in said Lyn knockout mice is deficient on its chromosome, methods such as examination by Southern blot or the like after separating DNA from a portion of a mouse tail base obtained by the method mentioned above, examination by Northern blot or the like after isolating RNA from the bone marrow cell or the like of said mice, and examination of the Lyn expression of said mice by Western blot or the like, can be exemplified.

[0016] In the same manner as that of the Lyn knockout mice, mice wherein the genetic function of Fc γ RI1B is deficient on its chromosome, that is, Fc γ RI1B knockout mice are generated. The Fc γ RI1B knockout mice (Fc γ RI-

IB^{-/-}) can be generated by the method as previously described (Nature 379, 346-349, 1996), in the same manner as the method of generating the Lyn knockout mice mentioned above, or the like.

[0017] A double knockout mouse wherein the genetic function of Lyn and Fc γ RIIB are both deficient on its chromosome, that is, a mouse wherein the deletion mutation of both molecules of Lyn and Fc γ RIIB are homozygotes (Lyn^{-/-}IIB^{-/-}), can be generated by mating the Lyn knockout mouse (Lyn^{-/-}) mentioned above and a mouse of Fc γ RIIB knockout mouse (Fc γ RIIB^{-/-}) lineage. Further, an example of the mouse wherein the genetic function of Fc γ RIIB is deficient on its chromosome in the present invention is the Fc γ RIIB knockout mice (Fc γ RIIB^{-/-}) mentioned above, more preferably, a Lyn^{+/-}Fc γ RIIB^{-/-}mice (IIB^{-/-}) that are littermates of double knockout mice (Lyn^{-/-}IIB^{-/-}).

[0018] As a method of screening a reaction accelerating or inhibitory substance in a type III allergy reaction through Fc γ RIII of the present invention, there is no particular limitation as long as it is a method of screening wherein a subject material is administered to the non-human model animal for type III allergy inflammation which does not develop anaphylaxis, a type I allergy, and specifically induces Arthus reaction, a type III allergy of the present invention, such as the double knockout mouse (Lyn^{-/-}IIB^{-/-}) mentioned above, followed by determination and evaluation of Fc γ RIII function in said non-human animal, or a method of screening wherein a bone marrow-derived mast cell induced from bone marrow cells derived from the non-human model animal for type III allergy inflammation which does not develop anaphylaxis, a type I allergy, and specifically induces Arthus reaction, a type III allergy of the present invention, such as the double knockout mouse (Lyn^{-/-}IIB^{-/-}) mentioned above, is contacted with a subject material in vitro, followed by determination and evaluation of Fc γ RIII function in said bone marrow-derived mast cell. When screening is conducted, it is preferable to make a comparative evaluation of the degree of Fc γ RIII function with a non-human animal wherein the genetic function of Fc γ RIIB is deficient on its chromosome, such as the aforementioned Fc γ RIIB knockout mouse (Fc γ RIIB^{-/-}), preferably a Lyn^{+/-}Fc γ RIIB^{-/-}-mouse (IIB^{-/-}) which is a littermate of the double knockout mouse (Lyn^{-/-}IIB^{-/-}).

[0019] As a method of determination and evaluation of Fc γ RIII function in the non-human animal mentioned above, for example, when a subject material is administered in vivo, a method of determination and evaluation of endorectal temperature after administration of antigen with the systemic passive anaphylaxis response intensity as an index, or a method wherein a substance contained in the granule discharged from eosinophils, mast cells and the like in the tissues are determined and evaluated by ELISA, Western blot, and the like, can be exemplified. When a subject material is contacted with bone marrow-derived mast cells in vitro, a method wherein the degranulation ability of said mast cells, the cytoplasmic calcium dynamics of mast cells, the tyrosine phosphorylation of

total protein of mast cells or the like are determined and evaluated, can be given as examples.

[0020] As a candidate substance of a reaction accelerating or inhibitory substance in a type III allergy reaction through Fc γ RIII, which can be obtained by the method of screening in the present invention, an agonist or antagonist of Fc γ RIII, a protein, peptide or the like that has action to the signaling pathway independent of Lyn, can be exemplified. Further, described is a remedy for diseases caused by type III allergy in the present invention, there is no particular limitation as long as an inhibitory substance that can be obtained from the method of screening a reaction accelerating or inhibitory substance in a type III allergy reaction through the Fc γ RIII according to any one of those previously described is used as an active ingredient. With the administration of said remedy to mammals and the like in an appropriate method, diseases caused by type III allergy reaction, such as serum sickness, glomerulonephritis, lupus nephritis, hypersensitivity pneumonitis, and the like can be cured.

[0021] The present invention will now be explained more specifically with the following examples, however, the technical scope of the invention is not limited to these examples.

Example A [Material and method]

A-1 (Mice)

[0022] Seven to 12-week old mice kept in a condition where they are not infected with specific pathogens were used for all the experiments. Mice wherein the deletion mutation of both molecules of Lyn and Fc γ RIIB are homozygotic (Lyn^{-/-}IIB^{-/-}) were generated by mating Lyn^{-/-} (Immunity 3, 549-560, 1995) and Fc γ RIIB^{-/-} (Nature 379, 346-349, 1996) lineage mice. Further, the littermates, Lyn^{+/-}Fc γ RIIB^{-/-}mice (IIB^{-/-}) were used as controls of Lyn^{-/-}Fc γ RIIB^{-/-}mice (Lyn^{-/-}IIB^{-/-}) mentioned above.

A-2 (Cells and antibodies)

[0023] Bone marrow-derived mast cells (BMMCs) were induced by culturing bone marrow cells with RPMI1640 [including 5 ng/ml mouse IL-3 (R&D Systems Inc, Minneapolis, MN), 10% immobilized fetal bovine serum, non-essential amino acid solution (GIBCO-BRL, Grand Island, NY), 100 IU/ml penicillin, 100 μ g/ml streptomycin and 10 μ M 2-mercaptoethanol at a final concentration]. As to mouse-anti trinitrophenyl hapten (TNP) IgE (IGELa2; American Type Culture Collection) and mouse-anti-TNP IgG1 (G1; Cell. Immunol. 145, 299-310, 1992), each of their hybridoma culture supernatants were purified by DEAE-cellulose column chromatography. As to the rat anti-mouse Fc γ RII/III (2.4G2, PharMigen, San Diego, CA), rabbit IgG anti-ovalbumin (OVA; Sigma, St Louis, MO), F(ab')₂ fragment of goat anti-rat IgG (Immunotech, Cedex, France) and anti-phosphorylation tyrosine antibody (4G10; upstate Biotechnology, Lake Plac-

id, NY), those purchased were used.

A-3 (Induction of systemic passive anaphylaxis)

[0024] Each of the mice generated in A-1 [$Lyn^{-/}Fc\gamma RIIB^{-/}$ (Lyn^{-/-}IIB^{-/-}) and $Lyn^{+/}Fc\gamma RIIB^{-/}$ (IIB^{-/-})] were sensitized with 20 μ g of anti-TNP IgG or 20 μ g of anti-TNP IgE by intravenous injection. Thirty minutes (IgG sensitization) or 24 hours (IgE sensitization) after the sensitization, 1 mg of TNP-linked OVA was dissolved in 100 ml PBS and this solution was intravenously injected to the mice to induce systemic passive anaphylaxis. Systemic passive anaphylaxis was induced to the controls by using the same amount of OVA instead of TNP-OVA during the induction. After the induction, a digital temperature indicator (Natume Seisakusyo Co., Osaka, Japan) with a temperature sensor probe was used to measure the endorectal temperature sequentially.

A-4 (Degranulation and cytokine release)

[0025] BMMCs (5×10^4 cell) were labeled with 6.6 μ Ci/ml of 5-[1,2-³H]-hydroxytryptamine creatinine sulfate (Amersham Pharmacia Biotech) for 16 hours, 5 μ g/ml of 2.4 G2 or 1 μ g/ml of mouse anti-TNP IgE was added at the remaining 30 minutes, and their BMMCs were sensitized. After the antibodies that did not bind to BMMCs were eliminated, 0.3 to 10 μ g/ml of goat anti-rat IgG F(ab')₂ fragment or 0.03 to 30 ng/ml of TNP-OVA was added and stimulated for one hour. The serotonin release rate (% of degranulation) was calculated in the same manner as reported previously (Cell 76, 519-529, 1994). The unlabeled BMMCs were stimulated in the same manner as mentioned above for cytokine release. After the stimulation, culture supernatant after 12 or 6 hours was used to measure the release of IL-4 or TNF- α , respectively. The amount of cytokine release was measured by using ELISA (Endogen, Inc., Woburn, MA).

A-5 (Cytoplasmic calcium dynamics)

[0026] BMMCs labeled with 2 μ M of Fura-2/acetoxymethyl ester (Molecular Probes, Eugene, OR) was sensitized under a condition of 25.degree. C. for ten minutes, with the use of 2 μ g/ml of biotin-binding mouse-anti TNP IgE or 5 μ g/ml of biotin-binding 2.4 G2. After eliminating the antibodies that did not bind, the sensitized cells mentioned above were stimulated with 10 μ g of streptavidin (Wako Pure Chemicals, Osaka, Japan) in 2 ml of PBS containing 1 mM of CaCl₂ and 1 mM of MgCl₂. As to the cytoplasmic calcium dynamics, the excitation of 340 and 360 nm was measured by using a fluorescence spectrophotometer (Hitachi model F4500, Hitachi Ltd., Tokyo, Japan), at an emission wavelength of 510 nm. The measurement and conversion of calcium concentration was conducted according to the method described in the literature (J. Biol. Chem. 260, 3440-3450).

A-6 (Immunoblotting analysis)

[0027] BMMCs (1×10^6) sensitized with 2.4G2 or biotin-binding mouse IgE were suspended in 100 μ l of PBS containing 1 mM of CaCl₂ and 1 mM of MgCl₂. Each of the suspensions were added with 30 μ g/ml of goat anti-rat IgG F(ab')₂ fragment or 5 μ g/ml of streptavidin, and treated under a condition of 37.degree. C. for 0.5, 1 or 5 minutes. Adding the same amount of ice-cold solubilized solution (50 mM of Tris-HCl (pH 7.4), 1% of Nonident P-40, 137 mM of NaCl, 2 mM of EDTA, 50 mM of NaF, 2 mM of NaVO₄, 1 mM of phenylmethylsulfonyl, 10 mg/ml of aprotinin, 5 mg/ml of leupeptine and 2 mg/ml of pepstatin) completed these treatments. The cytolytic solution wherein the nucleus fraction had been eliminated was used for examination of phosphorylation of proteins. Anti-phosphorylation tyrosine antibody (4G10) was used to conduct immunoblotting.

20 A-7 (Reverse cutaneous passive Arthus reaction)

[0028] Dorsal intracutaneous administration of physiological saline containing 0, 16 or 80 pg of rabbit anti-OVA IgG was performed to each of the mice obtained from Example A-1, whose trunk had been shaved. Immediately after, 200 μ l of physiological saline containing 1 mg of OVA was intravenously injected to the mice. These mice were killed after eight hours, and the dorsal skin was collected. The method according to Bradley et al. (J. Invest. Dermatol. 78, 206-209, 1982) was used as a reference for the Myeloperoxidase (MPO) assay. Simply, the portions that developed inflammation were excised as small pieces of tissues (12.5 mm²), homogenized with 400 μ l of 50 mM phosphate solution (pH 6.0), further added with hexadecyltrimethylammonium bromide (HTAB; Sigma) to a concentration of 0.5%, crushed by sonication for 20 seconds, and freeze thawing was repeated three times to generate extracts. These extracts were centrifuged for 15 minutes at 14,000 rpm, and the supernatant obtained was used for measuring the MPO activity. 20 μ l of these supernatant and 200 μ l of substrate solution [50 mM of phosphate solution (pH 6.0), 0.167 mg/ml of o-dianisidine dihydrochloride (Sigma) and 0.0005% of hydrogen peroxide (Wako Pure Chemical)] were mixed, and the change of color of the substrate solution was measured at an absorbance of 460 nm. The MPO activity obtained from 0.25 μ l of total mouse blood was calculated as 1 unit. For histological examination, the pieces of skin were fixed with 10% (vol/vol) neutral buffer formalin solution, made to paraffin pieces, followed by hematoxylin eosin staining.

Example B [Results]

55 B-1 (Deficiency of Fc γ RIII function in systemic passive anaphylaxis of $Lyn^{-/}Fc\gamma RIIB^{-1}$ mice)

[0029] It has been clarified from the previous studies

that Lyn-deficient mice cannot develop cutaneous passive anaphylaxis caused by IgE. This fact indicates that Lyn plays an important role in the downstream of the signaling of Fc ϵ RI on the mast cell (Cell 83, 301-311, 1995). The present inventors used the Lyn and Fc γ RIIB double deficient mice (Lyn^{-/-}Fc γ RIIB^{-/-}mice: Lyn^{-/-}IIB^{-/-}) lineage described in Example A-1, in order to eliminate the Fc γ RIIB (Annu. Rev. Immunol. 15, 203-234, 1997; J. Exp. Med. 189, 1573-1579, 1999; Nature 379, 346-349, 1996), which acts in a suppressive way against the response through Fc γ RIII. This was done in order to examine the significance of the role of Lyn in the downstream of the signaling of Fc γ RIII, when systemic passive anaphylaxis is induced with IgG-immunocomplex.

[0030] Following the method described in Example A-3, systemic passive anaphylaxis was induced to the double deficient mouse and control mouse, by administration of hapten-specific antibody [anti-TNP IgG1 (Figure 1 left; n=4) or anti-TNP IgE (Figure 1 right; n=6)] and antigen (TNP-OVA) through the coccygeal vein. The decrease in endorectal temperature from the time the antigen was administered was measured sequentially with the response intensity of the systemic passive anaphylaxis as an index. The results are shown in Figure 1. It was confirmed that in the stimulation of IgG and IgE, the control mouse showed obvious response, whereas the double deficient mouse clearly showed reduced response. It was revealed that since the response is reduced in double deficient mouse, the Lyn activity in mast cell is necessary for anaphylaxis through Fc γ RIII as well as in anaphylaxis through Fc ϵ RI. As to control experiment (Figure 1 upper case), endorectal temperature was measured in the same manner as the method described above, except that antibody was not administered to each of the mice mentioned above.

B-2 (Reduction of Fc γ RIII function in the BMMCs induced from Lyn deficient mice)

[0031] Next, in order to examine the degranulation ability of mast cells as an immediate response, and also as a main factor that develops anaphylaxis, functional analysis was conducted by examining the serotonin release using the culture BMMCs. Fc RIII or Fc ϵ RI was gradually crosslinked to induce the activity of mast cell, and the radiation-labeled serotonin released in the culture supernatant was measured (Figure 2). Degranulation of BMMCs were induced by crosslinking Fc γ RIII and Fc ϵ RI with 2.42G2 and goat anti-rat IgG1 F(ab')₂ (Figure 2 left) or anti-TNP IgE and TNP-OVA (Figure 2 right). As to degranulation, serotonin released in the culture supernatant one hour after stimulation was determined according to the method described in Example A-4. It was revealed from these results that the double deficient mouse-derived BMMCs show low response to weak stimulation (1 to 3 pg/ml of anti-rat IgG and 0.3 to 3 ng/ml of TNP-OVA) by stimulation through Fc γ RIII and Fc ϵ RI. On the other hand, it was also found out that the same

level of degranulation was shown for high stimulation in double deficient mouse-derived BMMCs. The differences between the double deficient mouse and control mouse were confirmed by an experiment repeated three times, and a cultured mast cell induced independently from the two mice were used for confirmation.

[0032] The present inventors then examined the cytoplasmic calcium dynamics and the total protein tyrosine phosphorylation of cells as characteristics of the deficiency of intracellular function of double deficient mouse-derived BMMCs. The BMMCs were stimulated in the method as described in Example A-5, and the cytoplasmic calcium dynamics was measured with a fluorescence spectrophotometer in an excitation at 510 nm. The results are shown in Figure 3A. The results showed that in double deficient mouse-derived BMMCs, the calcium dynamics by stimulation through Fc γ RIII or Fc ϵ RI reduced. This response was affected especially at an early stage (< 150 seconds) after induction, and was sufficiently induced in a later stage (> 300 seconds). The arrow in the Figure shows the cross linkage by streptavidin.

[0033] Further, BMMCs were stimulated in the method as described in Example A-5, the reaction was completed in the same manner as described in Example A-6, and immunoblotting was conducted to the cytolytic solution wherein the nucleus fraction had been eliminated (equivalent to 2.5 × 10⁴ per 1 lane) by using an anti-phosphorylation tyrosine monoclonal antibody (anti-pTyr: 4G10). The results are shown in Figure 3B. As is also clear from the results, it was revealed that five minutes after the stimulation, there was an effect in the induction of tyrosine phosphorylation in double deficient mouse-derived BMMCs. In addition, the expression of Fc γ RIII, Fc ϵ RI and c-kit, the proliferation by IL-3 and the uptake of serotonin was normal in double deficient mouse-derived BMMCs. This fact indicates that in double deficient mouse-derived BMMCs, functional abnormality (deficiency) was generated, not the differentiation abnormality such as small amount of expression of FcRs. These results in vitro imitated the results in vivo, and indicated at least that in the immediate stage of activation of mast cells, Lyn is important to the activation of signaling of FcRs.

B-3 (Normal function of Fc γ RIII to cytokine production in BMMCs of double deficient mice)

[0034] It has been revealed cytokines are newly produced by stimulation through FcR in mast cells (Nature 339, 64-67, 1989; J. Exp. Med. 170, 245-257, 1989; Nature 346, 274-276, 1990; Int. Arch. Allergy Immunol. 107, 158-159, 1995). The cytokines TNF- α and IL-4 that are well studied with regard to the activation of mast cells, are actually released in two hours, three hours or several hours after stimulation through FcR. It has been indicated that the cytokine release of mast cell is important to the onset of tissue destruction involving mast cell (Blood 94, 3855-3863, 1999; Immunology 77, 422-427, 1992; Sci-

ence 258, 1957-1959, 1992) and allergy (Allergy 50, 851-862, 1995). Based on these facts, the amount of production of TNF- α and IL-4 from BMMCs induced by stimulation through Fc γ R was examined. The BMMCs were stimulated for a few hours according to the method described in Example A-4 to crosslink Fc γ R, under a condition wherein anti-Fc γ RII/III antibody (2.4G2) and various concentrations of secondary antibodies exist. The results are shown in Figure 4. The results, contrary to the results obtained by degranulation and biochemical assay shown in Figures 2 and 3, did not show effect in the induction of TNF- α and IL-4 in double deficient mouse-derived BMMCs. These results indicate that the cytokine gene is activated regardless of Lyn activity in the downstream of Fc γ RIII signaling, and suggests the existence of a signaling mechanism sufficient for the induction of cytokine production in the mast cell.

B-4 (Normal function of Fc γ RIII to reverse cutaneous passive Arthus reaction in Lyn deficient mice)

[0035] Based on the result mentioned above wherein the production of cytokine does not depend on Lyn in vitro, the reverse cutaneous passive Arthus reaction, where cytokine is thought to be important to the expression thereof, was examined. This reverse cutaneous passive Arthus reaction is an inflammatory model caused by immunocomplex in vivo, and is revealed that it depends on the Fc γ RIII function on the mast cell (Science 265, 1095-1098, 1994; Immunity 5, 387-390; J. Clin. Invest. 99, 915-925, 1997; J. Clin. Invest. 99, 901-914, 1997; Immunity 5, 181-188, 1996). The MPO (myeloperoxidase) activity was measured according to the method as described in Example A-7 mentioned above, and examination by histology was also conducted. The results are shown in Figure 5. In Figure 5 (A), the infiltration rate of neutrophil is presented by the MPO activity (mean value \pm standard deviation of five mice wherein 1 unit is equivalent to MPO activity in 0.25 μ l) of the inflammatory site eight hours after administration of antigen. In Figure 5 (B), the histological change stained by hematoxylin eosin eight hours after induction of inflammation is shown together with a control sample (-) in which physiological saline had been intracutaneously administered (all photographs show observation at 40 magnifications). It was revealed from these results that the induction and histological view of MPO activity are in the same level for both the double deficient mice and control mice. It is clear that the number of mast cells in the skin is normal for the double deficient mice. It was revealed that the signaling activity that does not depend on Lyn of Fc γ RIII is sufficient to develop reverse cutaneous passive Arthus reaction, and that Lyn is not indispensable for the start of reaction at the later period of mast cells.

Industrial Applicability

[0036] The non-human model animal for type III allergy

inflammation in the present invention that does not develop anaphylaxis, a type I allergy, and can specifically induce Arthus reaction, a type III allergy, which is a double knockout mouse wherein the genetic function of Lyn and Fe γ IIB are deficient on its chromosome, is not affected by type I allergy, and is useful as an experimental model animal capable of evaluating type III allergy inflammation independently. Further, screening for an allergy reaction accelerating or inhibitory substance specific to type III allergy reaction through Fc γ RIII can be done by using said experimental model animal. There is a possibility that the inhibitory substance obtained by screening can be used as a remedy for diseases caused by type III allergy reaction.

Claims

1. A non-human model animal for type III allergy inflammation wherein the genetic function of Lyn and Fc γ IB are deficient on its chromosome, wherein the animal does not develop anaphylaxis, a type I allergy, and specifically induces Arthus reaction, a type III allergy.
2. The non-human model animal for type III allergy inflammation according to claim 1, wherein the non-human animal is a rodent.
3. The non-human model animal for type III allergy inflammation according to any of claims 1 or 2, wherein the rodent is a mouse.
4. A method of screening a reaction accelerating or inhibitory substance in a type III allergy reaction through γ RIII, wherein a subject material is administered to the non-human model animal for type III allergy inflammation according to any of claims 1 to 3, followed by determination and evaluation of Fc γ RIII function of the non-human animal.
5. The method of screening a reaction accelerating or inhibitory substance in a type III allergy reaction through Fc γ RIT1 according to claim 4, wherein the determination and evaluation of Fc γ RIII function of the non-human animal is a determination and evaluation of endorectal temperature after administration of antigen, with a systemic passive anaphylaxis response intensity as an index.
6. The method of screening a reaction accelerating or inhibitory substance in a type III allergy reaction through Fc γ RIII, wherein a bone marrow-derived mast cell induced from a bone marrow cell derived from the non-human model animal for type III allergy inflammation according to any of claims 1 to 3, is contacted with a subject material in vitro, followed by determination and evaluation of Fc γ RIII function

of the bone marrow-derived mast cell.

7. The method of screening a reaction accelerating or inhibitory substance in a type III allergy reaction through FcγRIII according to claim 6, wherein the determination and evaluation of FcγRIII function of the bone marrow-derived mast cell is a determination and evaluation of degranulation ability of mast cell, cytoplasmic calcium dynamics of mast cell, or tyrosine phosphorylation of total protein of mast cell.
8. The method of screening a reaction accelerating or inhibitory substance in a type III allergy reaction through the FcγRIII according to any of claims 4 to 7, wherein the method uses the non-human model animal for type III allergy inflammation according to any of claims 1 to 3 and a non-human animal wherein the genetic function of FcγIIB is deficient on its chromosome.

Patentansprüche

1. Nicht-menschliches Modelltier für die allergische Entzündung vom Typ III, wobei die genetische Funktion von Lyn und FcγIIB auf dessen Chromosom defizient sind, wobei das Tier keine Anaphylaxe, eine Allergie vom Typ I, entwickelt, und spezifisch eine Arthus-Reaktion, eine Allergie vom Typ III, induziert.
2. Nicht-menschliches Modelltier für eine allergische Entzündung vom Typ III gemäß Anspruch 1, wobei das nicht-menschliche Tier ein Nagetier ist.
3. Nicht-menschliches Modelltier für eine allergische Entzündung vom Typ III gemäß einem der Ansprüche 1 oder 2, wobei das Nagetier eine Maus ist.
4. Verfahren zum Screenen nach einer reaktionsbeschleunigenden oder reaktionshemmenden Substanz in einer allergischen Reaktion vom Typ III durch FcγRIII, wobei an das nicht-menschliche Modelltier für eine allergische Entzündung vom Typ III gemäß einem der Ansprüche 1 bis 3 ein Testmaterial verabreicht wird, gefolgt von der Bestimmung und Evaluierung der FcγRIII-Funktion des nicht-menschlichen Tieres.
5. Verfahren zum Screenen nach einer reaktionsbeschleunigenden oder reaktionshemmenden Substanz bei einer allergischen Reaktion vom Typ III durch FcγRIII gemäß Anspruch 4, wobei die Bestimmung und die Evaluierung der FcγRIII-Funktion des nicht-menschlichen Tieres eine Bestimmung und Evaluierung der endorektalen Temperatur nach Verabreichung von Antigen ist, mit einer systemisch passiven anaphylaktischen Antwortintensität als einem Index.

6. Verfahren zum Screenen nach einer reaktionsbeschleunigenden oder reaktionshemmenden Substanz bei einer allergischen Reaktion vom Typ III durch FcγRIII, wobei eine vom Knochenmark abgeleitete Mastzelle, die von einer aus einem nicht-menschlichen Modelltier für die allergische Entzündung vom Typ III gemäß einem der Ansprüche 1 bis 3 abgeleiteten Knochenmarkzelle induziert ist, mit einem Testmaterial *in vitro* in Kontakt gebracht wird, gefolgt von der Bestimmung und Evaluierung der FcγRIII-Funktion der vom Knochenmark abgeleiteten Mastzelle.
7. Verfahren zum Screenen nach einer reaktionsbeschleunigenden oder reaktionshemmenden Substanz bei einer allergischen Reaktion vom Typ III durch FcγRIII gemäß Anspruch 6, wobei die Bestimmung und Evaluierung der FcγRIII-Funktion der vom Knochenmark abgeleiteten Mastzelle eine Bestimmung und Evaluierung der Degranulationsfähigkeit der Mastzelle, der zytoplasmatischen Calciumdynamik der Mastzelle oder der Tyrosinphosphorylierung des Gesamtproteins der Mastzelle ist.
8. Verfahren zum Screenen nach einer reaktionsbeschleunigenden oder reaktionshemmenden Substanz bei einer allergischen Reaktion vom Typ III durch das FcγRIII gemäß einem der Ansprüche 4 bis 7, wobei bei dem Verfahren das nicht-menschliche Modelltier für die allergische Entzündung vom Typ III gemäß einem der Ansprüche 1 bis 3 und ein nicht-menschliches Tier, bei dem die genetische Funktion von FcγIIB auf dessen Chromosom defizient ist, verwendet wird.

Revendications

1. Animal modèle non humain pour une inflammation allergique de type III chez lequel la fonction génétique de Lyn et de FcγIIB est déficiente sur son chromosome, où l'animal ne développe pas d'anaphylaxie, d'allergie de type 1, et induit spécifiquement une réaction d'Arthus, une allergie de type III.
2. Animal modèle non humain pour une inflammation allergique de type III selon la revendication 1, où l'animal non humain est un rongeur.
3. Animal modèle non humain pour une inflammation allergique de type III selon l'une quelconque des revendications 1 ou 2, où le rongeur est une souris.
4. Procédé de criblage d'une substance accélératrice ou inhibitrice de réaction dans une réaction allergique de type III par l'intermédiaire de FcγRIII, dans lequel un matériau sujet est administré à l'animal modèle non humain pour une inflammation allergi-

que de type III selon l'une quelconque des revendications 1 à 3, ceci suivi de la détermination et de l'évaluation de la fonction de Fc γ RIII de l'animal non humain.

- 5
5. Procédé de criblage d'une substance accélératrice ou inhibitrice de réaction dans une réaction allergique de type III par l'intermédiaire de Fc γ RIII selon la revendication 4, dans lequel la détermination et l'évaluation de la fonction de Fc γ RIII de l'animal non humain est une détermination et une évaluation de la température endorectale après l'administration de l'antigène, avec une intensité de la réponse d'anaphylaxie passive systémique en tant qu'index.
- 10
- 15
6. Procédé de criblage d'une substance accélératrice ou inhibitrice de réaction dans une réaction allergique de type III par l'intermédiaire de Fc γ RIII, dans lequel un mastocyte dérivé de la moelle osseuse induit à partir d'une cellule de la moelle osseuse dérivée de l'animal modèle non humain pour une inflammation allergique de type III selon l'une quelconque des revendications 1 à 3, est mis en contact avec un matériau sujet *in vitro*, ceci suivi de la détermination et de l'évaluation de la fonction de Fc γ RIII du mastocyte dérivé de la moelle osseuse.
- 20
- 25
7. Procédé de criblage d'une substance accélératrice ou inhibitrice de réaction dans une réaction allergique de type III par l'intermédiaire de Fc γ RIII selon la revendication 6, dans lequel la détermination et l'évaluation de la fonction de Fc γ RIII du mastocyte dérivé de la moelle osseuse est une détermination et une évaluation de la capacité de dégranulation du mastocyte, de la dynamique du calcium cytoplasmique du mastocyte ou de la phosphorylation des tyrosines des protéines totales du mastocyte.
- 30
- 35
8. Procédé de criblage d'une substance accélératrice ou inhibitrice de réaction dans une réaction allergique de type III par l'intermédiaire de Fc γ RIII selon l'une quelconque des revendications 4 à 7, où le procédé utilise l'animal modèle non humain pour une inflammation allergique de type III selon l'une quelconque des revendications 1 à 3 et un animal non humain chez lequel la fonction génétique de Fc γ IIB est déficiente sur son chromosome.
- 40
- 45

50

55

FIG 1




FIG 2




FIG 3





FIG 4





FIG 5



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

- *Cell*, 1993, vol. 75, 969-976 [0004] [0005]
- *Cell*, 1994, vol. 76, 519-529 [0004] [0005] [0025]
- *Nature*, 1996, vol. 379, 346-349 [0004] [0016] [0022] [0029]
- *Immunity*, 1996, vol. 5, 181-188 [0004] [0006] [0035]
- *Nature*, 1994, vol. 369, 753-756 [0004]
- *J. Immunol.*, 1994, vol. 152, 3378-3390 [0004]
- *Proc. Natl. Acad. Sci. USA*, 1994, vol. 91, 6835-6839 [0004]
- *Science*, 1994, vol. 265, 1095-1098 [0005] [0006] [0035]
- *Immunity*, vol. 5, 387-390 [0005] [0006] [0035]
- *J. Exp. Med.*, 1999, vol. 189, 187-194 [0005]
- *J. Exp. Med.*, 2000, vol. 191, 1611-1616 [0005]
- *Kidney Int.*, 1998, vol. 54, 1166-1174 [0005]
- *Eur. J. Immunol.*, 2000, vol. 30, 1182-1190 [0005]
- *Blood*, 1999, vol. 94, 3855-3863 [0005] [0034]
- *Science*, 1998, vol. 279, 1052-1054 [0005]
- *J. Exp. Med.*, 2000, vol. 191, 899-906 [0005]
- *Annu. Rev. Immunol.*, 1998, vol. 16, 421-432 [0005]
- *Annu. Rev. Immunol.*, 1997, vol. 15, 203-234 [0005] [0029]
- Fc receptor genetics and the manipulation of genes in the study of FcR biology. **Takai, T. ; J. V. Ravetch.** Immunoglobulin Receptors and their Physiological and Pathological Roles in Immunity. Kluwer Academic Publishers, 1998, 37-48 [0005]
- *J. Clin. Invest.*, 1997, vol. 99, 915-925 [0006] [0035]
- *J. Clin. Invest.*, 1997, vol. 99, 901-914 [0006] [0035]
- *J. Exp. Med.*, 1999, vol. 189, 1573-1579 [0006] [0029]
- *J. Exp. Med.*, 1996, vol. 184, 2385-2392 [0006]
- *Eur. J. Immunol.*, 2000, vol. 30, 481-490 [0006]
- *Int. J. Biochem. Cell. Biol.*, 1997, vol. 29, 397-400 [0007]
- *Annu. Rev. Immunol.*, 1999, vol. 17, 555-592 [0007]
- *Cell*, 1995, vol. 83, 301-311 [0007] [0029]
- *Immunity*, 1995, vol. 3, 549-560 [0007] [0014] [0022]
- *Immunity*, 1997, vol. 7, 69-81 [0007]
- *J. Immunol.*, 1997, vol. 158, 2350-2355 [0007]
- *Cell. Immunol.*, 1992, vol. 145, 299-310 [0023]
- *J. Biol. Chem.*, vol. 260, 3440-3450 [0026]
- **Bradley et al.** *J. Invest. Dermatol.*, 1982, vol. 78, 206-209 [0028]
- *Nature*, 1989, vol. 339, 64-67 [0034]
- *J. Exp. Med.*, 1989, vol. 170, 245-257 [0034]
- *Nature*, 1990, vol. 346, 274-276 [0034]
- *Int. Arch. Allergy Immunol.*, 1995, vol. 107, 158-159 [0034]
- *Immunology*, 1992, vol. 77, 422-427 [0034]
- *Science*, 1992, vol. 258, 1957-1959 [0034]
- *Allergy*, 1995, vol. 50, 851-862 [0034]